Prophylaxis of Venous Thromboembolism After Bariatric Surgery

Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery.

This study is a prospective evaluation of the relationship between lean body weight and anti-Xa activity and 5700 International Units (IU) nadroparin 4 hours after subcutaneous administration in morbidly obese patients after bariatric surgery.

There is no guideline for postoperative thromboembolic prevention in morbidly obese patients.

The investigators goal is to examine which dose of nadroparin is effective.

Inclusion Criteria:

• Approval for Roux-en-Y gastric bypass
• Total body weight > 140 kg

Exclusion Criteria:

• Renal impairment (GFR < 30ml/min and/ or serum creatinin > 150 micromol/ml)
• Coagulation disorders
• Use of vitamin K antagonists (such as acenocoumarol) pregnancy